Literature DB >> 16336036

Prevalence, associated risks, and treatment patterns of insomnia.

Thomas Roth1.   

Abstract

Insomnia, the most commonly reported sleep problem, affects about one third of the adult American population. Insomnia impairs the individual's functioning, diminishes his or her quality of life, and contributes to accidents, health care costs, and problems at work. Insomnia is frequently comorbid with physical and mental illness, as either a consequence or a contributing factor. In particular, considerable research supports a strong association between insomnia and depression. Because the majority of individuals who have trouble sleeping attempt to treat the problem independently using over-the-counter medications or alcohol, insomnia is undertreated by health care providers, despite its serious consequences.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16336036

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  26 in total

1.  A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia.

Authors:  Sonia Ancoli-Israel; Andrew D Krystal; W Vaughn McCall; Kendyl Schaefer; Amy Wilson; Raymond Claus; Robert Rubens; Thomas Roth
Journal:  Sleep       Date:  2010-02       Impact factor: 5.849

2.  Sleeping problems and suicide in 75,000 Norwegian adults: a 20 year follow-up of the HUNT I study.

Authors:  Johan Håkon Bjørngaard; Ottar Bjerkeset; Pål Romundstad; David Gunnell
Journal:  Sleep       Date:  2011-09-01       Impact factor: 5.849

3.  Insomnia and the performance of US workers: results from the America insomnia survey.

Authors:  Ronald C Kessler; Patricia A Berglund; Catherine Coulouvrat; Goeran Hajak; Thomas Roth; Victoria Shahly; Alicia C Shillington; Judith J Stephenson; James K Walsh
Journal:  Sleep       Date:  2011-09-01       Impact factor: 5.849

4.  Prevalence and polysomnographic correlates of insomnia comorbid with medical disorders.

Authors:  Rohit Budhiraja; Thomas Roth; David W Hudgel; Pooja Budhiraja; Christopher L Drake
Journal:  Sleep       Date:  2011-07-01       Impact factor: 5.849

Review 5.  ACS chemical neuroscience molecule spotlight on Suvorexant.

Authors:  Corey R Hopkins
Journal:  ACS Chem Neurosci       Date:  2012-09-19       Impact factor: 4.418

6.  Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia.

Authors:  Geert Mayer; Sherry Wang-Weigand; Barbara Roth-Schechter; Reiner Lehmann; Corinne Staner; Markku Partinen
Journal:  Sleep       Date:  2009-03       Impact factor: 5.849

7.  Insomnia in chronic renal patients on dialysis in Saudi Arabia.

Authors:  Hamdan H Al-Jahdali; Haithm A Khogeer; Waleed A Al-Qadhi; Salim Baharoon; Hani Tamim; Fayez F Al-Hejaili; Saeed M Al-Ghamdi; Abdullah A Al-Sayyari
Journal:  J Circadian Rhythms       Date:  2010-06-14

8.  Association of insomnia with quality of life, work productivity, and activity impairment.

Authors:  Susan C Bolge; Justin F Doan; Hema Kannan; Robert W Baran
Journal:  Qual Life Res       Date:  2009-03-14       Impact factor: 4.147

9.  Effect of retirement on sleep disturbances: the GAZEL prospective cohort study.

Authors:  Jussi Vahtera; Hugo Westerlund; Martica Hall; Noora Sjösten; Mika Kivimäki; Paula SalO; Jane E Ferrie; Markus Jokela; Jaana Pentti; Archana Singh-Manoux; Marcel Goldberg; Marie Zins
Journal:  Sleep       Date:  2009-11       Impact factor: 5.849

10.  Update on the safety considerations in the management of insomnia with hypnotics: incorporating modified-release formulations into primary care.

Authors:  Joseph A Lieberman
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.